{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:17:12Z","timestamp":1789820232166,"version":"4.0.1"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec><jats:title>Introduction:<\/jats:title><jats:p>Anaplastic lymphoma kinase (<jats:italic toggle=\"yes\">ALK)<\/jats:italic>gene rearrangements are observed in about 4% to 8% non\u2013small cell lung cancer (NSCLC).<jats:italic toggle=\"yes\">ALK<\/jats:italic>+ tumors have been associated with increased pleural and pericardial disease. Our primary objective was to determine the uncommon sites of metastasis of<jats:italic toggle=\"yes\">ALK<\/jats:italic>+ NSCLC. Secondary objectives included study of coexisting mutations and factors impacting survival of<jats:italic toggle=\"yes\">ALK<\/jats:italic>+ NSCLC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>All patients with metastatic<jats:italic toggle=\"yes\">ALK<\/jats:italic>+ NSCLC at the City of Hope Cancer Center in Duarte, California from 2010 to 2017 were selected for retrospective chart review. The demographic variables were collected. The molecular statuses of patients were evaluated through commercially available platforms for next-generation sequencing. Three-dimensional volumetric images were generated for the primary lesion and different sites of metastasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Sixty two patients with<jats:italic toggle=\"yes\">ALK<\/jats:italic>+ NSCLC were identified from 2010 to 2017. The median age was 59 with 36 (58%) female individuals and only 20 (32%) smokers. Twenty four patients had uncommon sites of metastasis which were thyroid, soft tissue, chest and abdominal wall, spleen, peritoneum, omentum, kidney, and ovary. Common characteristics of the primary lesions were right upper lobe location (N=23 [37%]), oval shape (N=22 [35%]), irregular margins (N=26 [42%]), solid lesions (N=27 [44%]), presence of pleural contact or effusion (N=22 [35%]). Twenty four patients had next-generation sequencing testing which showed coexisting mutations such as<jats:italic toggle=\"yes\">TP53<\/jats:italic>(N=8),<jats:italic toggle=\"yes\">EGFR<\/jats:italic>(N=5),<jats:italic toggle=\"yes\">KRAS<\/jats:italic>(N=3). Patients with uncommon sites of metastasis had a decreased median survival compared with common sites (39 vs. 82\u2009m,<jats:italic toggle=\"yes\">P<\/jats:italic>=0.046).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>In NSCLC,<jats:italic toggle=\"yes\">ALK<\/jats:italic>rearrangements may not be mutually exclusive mutations and can present with unique radiographic patterns. Patients with uncommon sites of metastasis may have worse outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1097\/coc.0000000000000508","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T11:48:50Z","timestamp":1550231330000},"page":"337-344","source":"Crossref","is-referenced-by-count":9,"title":["Anaplastic Lymphoma Kinase (ALK)-positive Tumors"],"prefix":"10.1097","volume":"42","author":[{"given":"Rohan","family":"Gupta","sequence":"first","affiliation":[{"name":"Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idoroenyi","family":"Amanam","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Rahmanuddin","sequence":"additional","affiliation":[{"name":"Diagnostic Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isa","family":"Mambetsariev","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Informatics, City of Hope Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charity","family":"Huang","sequence":"additional","affiliation":[{"name":"Diagnostic Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Reckamp","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit","family":"Vora","sequence":"additional","affiliation":[{"name":"Diagnostic Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230903","first-page":"16","article-title":"The global and regional burden of cancer","volume":"2014","author":"Forman","year":"2014","journal-title":"World Cancer Report"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","article-title":"Lung cancer: current therapies and new targeted treatments","volume":"389","author":"Hirsch","year":"2016","journal-title":"Lancet"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4\u2013ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non\u2013small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J Clin Oncol"},{"key":"R6-20230903"},{"key":"R8-20230903","author":"Waskom"},{"key":"R9-20230903","article-title":"Pandas: a foundational Python library for data analysis and statistics","author":"McKinney","year":"2011","journal-title":"Python High Performance Sci Comput"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/JTO.0b013e3181c4dedb","article-title":"ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer","volume":"4","author":"Solomon","year":"2009","journal-title":"J Thorac Oncol"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1158\/1078-0432.CCR-10-1591","article-title":"Targeting anaplastic lymphoma kinase in lung cancer","volume":"17","author":"Shaw","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1634\/theoncologist.2015-0497","article-title":"Comprehensive genomic profiling identifies a subset of crizotinib-responsive ALK-rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization","volume":"21","author":"Ali","year":"2016","journal-title":"Oncologist"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","article-title":"Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase\u2013positive non\u2013small-cell lung cancer: a randomized, multicenter phase II trial","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3390\/cancers9090118","article-title":"EML4-ALK variants: biological and molecular properties, and the implications for patients","volume":"9","author":"Sabir","year":"2017","journal-title":"Cancers"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12967-016-1061-z","article-title":"Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants","volume":"14","author":"Cha","year":"2016","journal-title":"J Transl Med"},{"key":"R21-20230903","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2015.65.8732","article-title":"Differential crizotinib response duration among ALK fusion variants in ALK-positive non\u2013small-cell lung cancer","volume":"34","author":"Yoshida","year":"2016","journal-title":"J Clin Oncol"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12885-016-2169-5","article-title":"Distribution and prognosis of uncommon metastases from non-small cell lung cancer","volume":"16","author":"Niu","year":"2016","journal-title":"BMC Cancer"},{"key":"R23-20230903","doi-asserted-by":"crossref","DOI":"10.1016\/j.trecan.2018.01.001","article-title":"The genetic\/non-genetic duality of drug \u2018resistance\u2019 in cancer","author":"Salgia","year":"2018","journal-title":"Trends Cancer"},{"key":"R24-20230903","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/s12094-013-1008-2","article-title":"Treatment outcome for patients with primary NSCLC and synchronous solitary metastasis","volume":"15","author":"Xu","year":"2013","journal-title":"Clin Transl Oncol"},{"key":"R25-20230903","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1002\/cncr.27409","article-title":"Oncogene status predicts patterns of metastatic spread in treatment\u2010naive nonsmall cell lung cancer","volume":"118","author":"Doebele","year":"2012","journal-title":"Cancer"},{"key":"R26-20230903","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00063","article-title":"Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non\u2013small-cell lung cancer","volume":"1","author":"Gainor","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"R27-20230903","first-page":"151","article-title":"Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus","volume":"1","author":"West","year":"2014","journal-title":"Case Rep Clin Pathol"},{"key":"R28-20230903","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000352086","article-title":"EML4-ALK-Positive pulmonary adenocarcinoma with an unusual metastatic pattern: a case report","volume":"6","author":"Diem","year":"2013","journal-title":"Case Rep Oncol"},{"key":"R29-20230903","first-page":"117","article-title":"EML4-ALK-positive lung adenocarcinoma presenting an unusual metastatic pattern in a 29-year-old woman who is alive and well in her third year follow up: a case report","volume":"22","author":"Tokat","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"R30-20230903","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s13402-017-0345-5","article-title":"Lung cancer-associated brain metastasis: molecular mechanisms and therapeutic options","volume":"40","author":"Yousefi","year":"2017","journal-title":"Cellular Oncol"},{"key":"R31-20230903","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11060-004-8093-6","article-title":"Brain metastases: epidemiology and pathophysiology","volume":"75","author":"Gavrilovic","year":"2005","journal-title":"J Neurooncology"},{"key":"R32-20230903","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.1988.6.9.1474","article-title":"Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis","volume":"6","author":"S\u00f8rensen","year":"1988","journal-title":"J Clin Oncol"},{"key":"R33-20230903","doi-asserted-by":"crossref","first-page":"e0161081","DOI":"10.1371\/journal.pone.0161081","article-title":"Imaging characteristics of driver mutations in EGFR, KRAS, and ALK among treatment-naive patients with advanced lung adenocarcinoma","volume":"11","author":"Park","year":"2016","journal-title":"PloS One"},{"key":"R34-20230903","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00330-015-3814-0","article-title":"CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer","volume":"26","author":"Rizzo","year":"2016","journal-title":"Eur Radiol"},{"key":"R35-20230903","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jtcvs.2012.11.019","article-title":"Solid tumors versus mixed tumors with a ground-glass opacity component in patients with clinical stage IA lung adenocarcinoma: prognostic comparison using high-resolution computed tomography findings","volume":"146","author":"Tsutani","year":"2013","journal-title":"J Thorac Cardiovas Surg"},{"key":"R36-20230903","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.athoracsur.2013.02.022","article-title":"Comparison of three measurements on computed tomography for the prediction of less invasiveness in patients with clinical stage I non\u2013small cell lung cancer","volume":"95","author":"Matsuguma","year":"2013","journal-title":"Ann Thorac Surg"},{"key":"R37-20230903","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/icvts\/ivw037","article-title":"Is volumetric 3-dimensional computed tomography useful to predict histological tumour invasiveness? Analysis of 211 lesions of cT1N0M0 lung adenocarcinoma","volume":"22","author":"Shikuma","year":"2016","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"R38-20230903","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1148\/radiol.14140789","article-title":"ALK molecular phenotype in non\u2013small cell lung cancer: CT radiogenomic characterization","volume":"272","author":"Yamamoto","year":"2014","journal-title":"Radiology"},{"key":"R39-20230903","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"R40-20230903","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1038\/bjc.2014.210","article-title":"Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts","volume":"110","author":"Li","year":"2014","journal-title":"Br J Cancer"},{"key":"R41-20230903","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/j.cllc.2017.04.006","article-title":"Coexistence of EGFR, KRAS, BRAF, and PIK3CA mutations and ALK rearrangement in a comprehensive cohort of 326 consecutive spanish nonsquamous NSCLC patients","volume":"18","author":"Martorell","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"R42-20230903","doi-asserted-by":"crossref","first-page":"59889","DOI":"10.18632\/oncotarget.17431","article-title":"Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases","volume":"8","author":"Russo","year":"2017","journal-title":"Oncotarget"},{"key":"R43-20230903","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/ng.3990","article-title":"Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers","volume":"49","author":"Blakely","year":"2017","journal-title":"Nat Genet"},{"key":"R44-20230903","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4132\/jptm.2016.03.09","article-title":"Non-small cell lung cancer with concomitant EGFR, KRAS, and ALK mutation: clinicopathologic features of 12 cases","volume":"50","author":"Lee","year":"2016","journal-title":"J Pathol Translational Med"},{"key":"R45-20230903","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/annonc\/mdu530","article-title":"Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor","volume":"26","author":"Won","year":"2014","journal-title":"Ann Oncol"},{"key":"R46-20230903","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.lungcan.2012.04.012","article-title":"Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation","volume":"77","author":"Lee","year":"2012","journal-title":"Lung Cancer"},{"key":"R47-20230903","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.cllc.2015.11.004","article-title":"Nonsquamous, non-small-cell lung cancer patients who carry a double mutation of EGFR, EML4-ALK or KRAS: frequency, clinical-pathological characteristics, and response to therapy","volume":"17","author":"Ulivi","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"R48-20230903","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.lungcan.2013.05.003","article-title":"A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene","volume":"81","author":"Chen","year":"2013","journal-title":"Lung Cancer"},{"key":"R49-20230903","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/annonc\/mdv067","article-title":"Concomitant EGFR and KRAS mutations in ALK-rearranged lung cancer","volume":"26","author":"Rossi","year":"2015","journal-title":"Ann Oncol"},{"key":"R50-20230903","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.lungcan.2014.09.011","article-title":"Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells","volume":"86","author":"Baldi","year":"2014","journal-title":"Lung Cancer"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000421-201904000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T20:32:03Z","timestamp":1720989123000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201904000-00002"}},"subtitle":["Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma"],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000508","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}